Current studentsExisting staffContact us
 

Assessment of microbial risk during Australian industrial practices for Escherichia coli O157:H7 in fresh cut-cos lettuce: a stochastic quantitative approach

Simple item page
dc.contributor.authorBozkurt Cekmer, H.
dc.contributor.authorBell, T.
dc.contributor.authorvan Ogtrop, F.
dc.contributor.authorPhan-Thien, K.-Y.
dc.contributor.authorMcConchie, R.
dc.date.issued2021
dc.description.abstractIntroduction Recurrent event rates after myocardial infarction (MI) remain unacceptably high, in part because of the continued growth and destabilization of residual coronary atherosclerotic plaques, which may occur despite lipid-lowering therapy. Inflammation is an important contributor to this ongoing risk. Recent studies have shown that the broad-acting anti-inflammatory agent, colchicine, may reduce adverse cardiovascular events in patients post-MI, although the mechanistic basis for this remains unclear. Advances in endovascular arterial wall imaging have allowed detailed characterization of the burden and compositional phenotype of coronary plaque, along with its natural history and responsiveness to treatment. One such example has been the use of optical coherence tomography (OCT) to demonstrate the plaque-stabilizing effects of statins on both fibrous cap thickness and the size of lipid pools within plaque. Methods The Phase 2, multi-centre, double-blind colchicine for coronary plaque modification in acute coronary syndrome (COCOMO-ACS) study will evaluate the effect of colchicine 0.5 mg daily on coronary plaque features using serial OCT imaging in patients following MI. Recruitment for the trial has been completed with 64 participants with non-ST elevation MI randomized 1:1 to colchicine or placebo in addition to guideline recommended therapies, including high-intensity statins. The primary endpoint is the effect of colchicine on the minimal fibrous cap thickness of non-culprit plaque over an 18-month period. Summary The COCOMO-ACS study will determine whether addition of colchicine 0.5 mg daily to standard post-MI treatment has incremental benefits on high-risk features of coronary artery plaques. If confirmed, this will provide new mechanistic insights into how colchicine may confer clinical benefits in patients with atherosclerotic cardiovascular disease.
dc.description.statementofresponsibilityHayriye Bozkurt, Tina Bell, Florisvan Ogtrop, Kim-Yen Phan-Thien, Robyn McConchie
dc.identifier.citationFood Microbiology, 2021; 95:103691-1-103691-12
dc.identifier.doi10.1016/j.fm.2020.103691
dc.identifier.issn0740-0020
dc.identifier.issn1095-9998
dc.identifier.orcidBozkurt Cekmer, H. [0000-0003-3702-0614]
dc.identifier.urihttps://hdl.handle.net/2440/132438
dc.language.isoen
dc.publisherElsevier
dc.relation.granthttp://purl.org/au-research/grants/arc/IC160100025
dc.rights© 2020 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.fm.2020.103691
dc.subjectLeafy greens; season; irrigation water; irrigation type; manure amended soil; QMRA
dc.subject.meshEscherichia coli O157
dc.subject.meshLettuce
dc.subject.meshPlant Leaves
dc.subject.meshManure
dc.subject.meshColony Count, Microbial
dc.subject.meshFresh Water
dc.subject.meshFood Contamination
dc.subject.meshAustralia
dc.subject.meshAgricultural Irrigation
dc.titleAssessment of microbial risk during Australian industrial practices for Escherichia coli O157:H7 in fresh cut-cos lettuce: a stochastic quantitative approach
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Agriculture, Food and Wine publications